Letter in Response to the Recently Published Review: Hyponatremia in Cirrhosis and End-Stage Liver Disease-Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan

被引：4

作者：

Abhyankar, A. ^{[1
]}

Robson, S. C. ^{[2
]}

Tapper, E. B. ^{[2
]}

Bonder, A. ^{[2
]}

机构：

[1] St Elizabeths Med Ctr, Dept Med, Brighton, MA USA

[2] Harvard Univ, Sch Med, Dept Med, Ctr Liver, Boston, MA 02215 USA

来源：

DIGESTIVE DISEASES AND SCIENCES | 2013年 / 58卷 / 03期

关键词：

V-2-RECEPTOR ANTAGONIST; ASCITES;

D O I：

10.1007/s10620-013-2573-5

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

引用

页码：889 / 890

页数：2

共 5 条

[1]

Hyponatremia in cirrhosis:: Results of a patient population survey [J].

Angeli, Paolo ;

Wong, Florence ;

Watson, Hugh ;

Gines, Pere .

HEPATOLOGY, 2006, 44 (06) :1535-1542

[2]

Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia [J].

Dahl, E. ;

Gluud, L. L. ;

Kimer, N. ;

Krag, A. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (07) :619-626

[3]

Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan [J].

Gaglio, Paul ;

Marfo, Kwaku ;

Chiodo, Joseph, III .

DIGESTIVE DISEASES AND SCIENCES, 2012, 57 (11) :2774-2785

[4]

PROGNOSTIC VALUE OF ARTERIAL-PRESSURE, ENDOGENOUS VASOACTIVE SYSTEMS, AND RENAL-FUNCTION IN CIRRHOTIC-PATIENTS ADMITTED TO THE HOSPITAL FOR THE TREATMENT OF ASCITES [J].

LLACH, J ;

GINES, P ;

ARROYO, V ;

RIMOLA, A ;

TITO, L ;

BADALAMENTI, S ;

JIMENEZ, W ;

GAYA, J ;

RIVERA, F ;

RODES, J .

GASTROENTEROLOGY, 1988, 94 (02) :482-487

[5]

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia [J].

Schrier, Robert W. ;

Gross, Peter ;

Gheorghiade, Mihai ;

Berl, Tomas ;

Verbalis, Joseph G. ;

Czerwiec, Frank S. ;

Orlandi, Cesare .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (20) :2099-2112

← 1 →